KAROLYN MINER: Open Payments
NPI 1447997481 · NORWICH, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,362 in 62 payments from 25 companies in 2025. Trend: 2023 $1,609 · 2024 $2,052 · 2025 $1,362
Food & beverage: $1,263Education: $100
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $141 |
| SOBI, INC | 2 | $128 |
| AstraZeneca Pharmaceuticals LP | 5 | $119 |
| Celgene Corporation | 6 | $118 |
| Merck Sharp & Dohme LLC | 5 | $106 |
| Janssen Biotech, Inc. | 4 | $78 |
| Genentech USA, Inc. | 4 | $75 |
| ABBVIE INC. | 3 | $68 |
| Eisai Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
Products named: REBLOZYL, KISQALI, KEYTRUDA, Lenvima, TAVALISSE, Enhertu, EPKINLY, SARCLISA.
Industry payments across CT — which companies pay providers there.
